Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

The Lancet · 2005 · 3.3K citations

Medicine, Internal Medicine, Pharmacology +13

PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL

Peter Tontonoz, László Nagy, Jacqueline G. Alvarez et al. · Cell · 1998 · 1.8K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

INFLUENCE OF PLAQUE CONFIGURATION AND STRESS DISTRIBUTION ON FISSURING OF CORONARY ATHEROSCLEROTIC PLAQUES

P. D. Richardson · The Lancet · 1989 · 1.3K citations

Medicine, Cardiology, Clinical Cardiology +8

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content.

Michael J. Davies, P. D. Richardson, N. J. Woolf et al. · Heart · 1993 · 1.1K citations · Full text

Medicine, Cardiology, Pathology +16